ZA965459B - Vaccines - Google Patents

Vaccines

Info

Publication number
ZA965459B
ZA965459B ZA965459A ZA965459A ZA965459B ZA 965459 B ZA965459 B ZA 965459B ZA 965459 A ZA965459 A ZA 965459A ZA 965459 A ZA965459 A ZA 965459A ZA 965459 B ZA965459 B ZA 965459B
Authority
ZA
South Africa
Prior art keywords
vaccines
Prior art date
Application number
ZA965459A
Other languages
English (en)
Inventor
Teresa Cabezon Silva
Patricia Marie Momim
Nathalie Marie-Josephe Garcon
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of ZA965459B publication Critical patent/ZA965459B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
ZA965459A 1995-06-29 1996-06-27 Vaccines ZA965459B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9513261.9A GB9513261D0 (en) 1995-06-29 1995-06-29 Vaccines

Publications (1)

Publication Number Publication Date
ZA965459B true ZA965459B (en) 1997-04-01

Family

ID=10776867

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA965459A ZA965459B (en) 1995-06-29 1996-06-27 Vaccines

Country Status (15)

Country Link
EP (1) EP0835318A2 (xx)
JP (1) JPH11508769A (xx)
KR (1) KR19990028505A (xx)
AU (1) AU6304996A (xx)
BR (1) BR9609258A (xx)
CA (1) CA2222456A1 (xx)
CZ (1) CZ422397A3 (xx)
GB (1) GB9513261D0 (xx)
HU (1) HUP9901901A3 (xx)
IL (1) IL122589A0 (xx)
NO (1) NO976060L (xx)
PL (1) PL324906A1 (xx)
TR (1) TR199701713T1 (xx)
WO (1) WO1997001640A2 (xx)
ZA (1) ZA965459B (xx)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997025429A1 (en) 1996-01-04 1997-07-17 Rican Limited Helicobacter pylori bacterioferritin
US5858389A (en) * 1996-08-28 1999-01-12 Shaker H. Elsherbini Squalene is an antiviral compound for treating hepatitis C virus carriers
AT405939B (de) * 1997-02-24 1999-12-27 Immuno Ag Verfahren zur inaktivierung von lipidumhüllten viren
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
GB9712347D0 (en) * 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
WO2000011186A1 (en) * 1998-08-21 2000-03-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified hcv peptide vaccines
CA2347099C (en) * 1998-10-16 2014-08-05 Smithkline Beecham Biologicals S.A. Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
ES2311478T3 (es) * 1999-11-19 2009-02-16 Csl Limited Composiciones de vacuna contra el hcv.
SG165981A1 (en) 2000-10-27 2010-11-29 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
EP2339035A1 (en) 2000-12-07 2011-06-29 Novartis Vaccines and Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US7501134B2 (en) 2002-02-20 2009-03-10 Novartis Vaccines And Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
AU2002249253A1 (en) * 2002-03-04 2002-07-08 Zagyansky, Yuly Universal antimicrobial treatment
EP2302039A1 (en) 2002-06-13 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Virus-like particles comprising HML-2 gag polypeptide
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
ATE466875T1 (de) 2002-11-15 2010-05-15 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CA2514328C (en) 2003-01-30 2020-01-14 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US9107831B2 (en) 2003-06-02 2015-08-18 Novartis Vaccines And Diagonstics, Inc. Immunogenic compositions containing microparticles comprising adsorbed toxoid and polysaccharide-containing antigens
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1670506B1 (en) 2003-10-02 2012-11-21 Novartis AG Liquid vaccines for multiple meningococcal serogroups
CA2559371C (en) 2004-03-09 2014-07-08 Chiron Corporation Influenza virus vaccines
EP1740217B1 (en) 2004-04-30 2011-06-15 Novartis Vaccines and Diagnostics S.r.l. Meningococcal conjugate vaccination
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
EP1766034B1 (en) 2004-05-21 2014-03-19 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for influenza virus vaccines
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
EP2277595A3 (en) 2004-06-24 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
US20090317420A1 (en) 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
AU2006208208B2 (en) 2005-01-27 2011-05-19 Children's Hospital & Research Center At Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
EP1858920B1 (en) 2005-02-18 2016-02-03 GlaxoSmithKline Biologicals SA Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
EP1858919B1 (en) 2005-02-18 2012-04-04 Novartis Vaccines and Diagnostics, Inc. Immunogens from uropathogenic escherichia coli
WO2007047749A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics Inc. Mucosal and systemic immunizations with alphavirus replicon particles
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
EP2357184B1 (en) 2006-03-23 2015-02-25 Novartis AG Imidazoquinoxaline compounds as immunomodulators
EP2054431B1 (en) 2006-06-09 2011-08-31 Novartis AG Conformers of bacterial adhesins
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
AU2008299376B2 (en) 2007-09-12 2013-02-28 Glaxosmithkline Biologicals S.A. GAS57 mutant antigens and GAS57 antibodies
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
BRPI0821240B8 (pt) 2007-12-21 2022-10-04 Novartis Ag formas mutantes de estreptolisina o
AU2009215364B2 (en) 2008-02-21 2014-09-18 Glaxosmithkline Biologicals S.A. Meningococcal fHBP polypeptides
CA2717870A1 (en) 2008-03-10 2009-09-17 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
SG186611A1 (en) 2008-12-09 2013-01-30 Pfizer Vaccines Llc Ige ch3 peptide vaccine
AU2010204139A1 (en) 2009-01-12 2011-08-11 Novartis Ag Cna_B domain antigens in vaccines against gram positive bacteria
JP2012519482A (ja) 2009-03-06 2012-08-30 ノバルティス アーゲー クラミジア抗原
US8679505B2 (en) 2009-04-14 2014-03-25 Novartis Ag Compositions for immunising against Staphylococcus aureus
CN102413838A (zh) 2009-04-30 2012-04-11 科勒制药集团有限公司 肺炎球菌疫苗及其用途
CA2765364C (en) 2009-06-15 2015-05-26 National University Of Singapore Influenza vaccine, composition, and methods of use
MX2012000395A (es) 2009-07-07 2012-02-28 Novartis Ag Inmunogenos conservados de escherichia coli.
JP2012532626A (ja) 2009-07-16 2012-12-20 ノバルティス アーゲー 無毒化されたＥｓｃｈｅｒｉｃｈｉａｃｏｌｉ免疫原
MX2012001194A (es) 2009-07-30 2012-03-07 Pfizer Vaccines Llc Peptidos tau antigenicos y usos de los mismos.
US20110076300A1 (en) 2009-08-27 2011-03-31 Mariagrazia Pizza Hybrid Polypeptides Including Meningococcal fHBP Sequences
EP2473605B1 (en) 2009-09-03 2018-04-11 Pfizer Vaccines LLC Pcsk9 vaccine
CN102695523A (zh) 2009-09-10 2012-09-26 诺华有限公司 针对呼吸道疾病的组合疫苗
SI2475384T1 (sl) * 2009-09-10 2016-12-30 Merial, Inc. Nove formulacije cepiva, ki obsegajo adjuvante, vsebujoče saponin
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
CA2776004A1 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
ES2812523T3 (es) 2009-09-30 2021-03-17 Glaxosmithkline Biologicals Sa Conjugación de polisacáridos capsulares de Staphylococcus aureus de tipo 5 y de tipo 8
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
US20130022633A1 (en) 2009-10-27 2013-01-24 University Of Florence MENINGOCOCCAL fHBP POLYPEPTIDES
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
CN107412754A (zh) 2009-12-22 2017-12-01 塞尔德克斯医疗公司 疫苗组合物
ES2707778T3 (es) 2009-12-30 2019-04-05 Glaxosmithkline Biologicals Sa Inmunógenos polisacáridos conjugados con proteínas portadoras de E. coli
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
ES2661569T3 (es) 2010-03-30 2018-04-02 Children's Hospital & Research Center At Oakland Proteínas de unión al factor H (fHbp) con propiedades alteradas y métodos de uso de las mismas
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
US9744228B2 (en) 2010-04-07 2017-08-29 Norvartis Ag Method for generating a parvovirus B19 virus-like particle
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
WO2011154863A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
EP3153578A1 (en) 2010-07-06 2017-04-12 Novartis Ag Norovirus derived immunogenic compositions and methods
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
EA025152B1 (ru) 2010-12-02 2016-11-30 Бионор Иммуно Ас Конструкция пептидного каркаса
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
JP6294076B2 (ja) 2011-01-06 2018-03-14 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ 多量体ペプチド
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
US10030052B2 (en) 2011-07-25 2018-07-24 Glaxosmithkline Biologicals Sa Parvovirus Vp1 unique region polypeptides and compositions thereof
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
TR201909110T4 (tr) 2011-09-14 2019-07-22 Glaxosmithkline Biologicals Sa Sakarit-protein glikokonjugatları yapmaya yönelik yöntemler.
JP2014531442A (ja) 2011-09-14 2014-11-27 ノバルティス アーゲー Ｅｓｃｈｅｒｉｃｈｉａｃｏｌｉワクチンの組み合わせ
JP6084631B2 (ja) 2011-12-08 2017-02-22 ノバルティス アーゲー Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ毒素ベースのワクチン
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
CN104321335A (zh) 2012-02-24 2015-01-28 诺华股份有限公司 菌毛蛋白质和组合物
CA2871520C (en) 2012-04-26 2020-12-29 Novartis Ag Antigens from non-typeable h. influenzae
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
CN105457021A (zh) 2012-05-04 2016-04-06 辉瑞公司 前列腺相关抗原及基于疫苗的免疫治疗疗法
MX2014014067A (es) 2012-05-22 2015-02-04 Novartis Ag Conjugado de serogrupo x de meningococo.
NZ702146A (en) 2012-06-06 2016-11-25 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
JP6283674B2 (ja) 2012-09-18 2018-02-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 外膜小胞
MX2015004171A (es) 2012-10-02 2015-10-22 Glaxosmithkline Biolog Sa Conjugados de sacaridos no lineales.
KR20150073943A (ko) 2012-10-03 2015-07-01 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
US9987344B2 (en) 2012-11-30 2018-06-05 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
EP3689375A1 (en) 2013-05-15 2020-08-05 The Governors Of The University Of Alberta E1e2 hcv vaccines and methods of use
KR102157200B1 (ko) 2014-01-21 2020-09-21 화이자 인코포레이티드 접합된 캡슐 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
CR20170020A (es) 2014-07-23 2017-08-10 Children´S Hospital & Res Center At Oakland Variantes de proteínas de unión al factor h y métodos de uso de estas
PL3244917T3 (pl) 2015-01-15 2023-07-17 Pfizer Inc. Kompozycje immunogenne do zastosowania w szczepionkach przeciwko pneumokokom
EP3302536A1 (en) 2015-06-03 2018-04-11 Affiris AG Il-23-p19 vaccines
EP3319988A1 (en) 2015-07-07 2018-05-16 Affiris AG Vaccines for the treatment and prevention of ige mediated diseases
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CN108778321A (zh) 2016-01-19 2018-11-09 辉瑞公司 癌症疫苗
KR102459629B1 (ko) 2017-01-20 2022-10-28 화이자 인코포레이티드 폐렴구균 백신에 사용하기 위한 면역원성 조성물
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
CN112912097A (zh) 2018-08-23 2021-06-04 葛兰素史密丝克莱恩生物有限公司 免疫原性蛋白和组合物
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP4051696A1 (en) 2019-11-01 2022-09-07 Pfizer Inc. Escherichia coli compositions and methods thereof
AU2021211012A1 (en) 2020-01-24 2022-08-25 Aim Immunotech Inc. Methods, compositions, and vaccines for treating a virus infection
EP4103587A1 (en) 2020-02-14 2022-12-21 Immunor AS Corona virus vaccine
JP2021132644A (ja) 2020-02-21 2021-09-13 ファイザー・インク 糖の精製
CA3173729A1 (en) 2020-02-23 2021-08-26 Pfizer Inc. Escherichia coli compositions and methods thereof
JP2023514825A (ja) 2020-02-26 2023-04-11 ヴェルシテック リミテッド コロナウイルス感染症に対するｐｄ－１ベースのワクチン
PE20231934A1 (es) 2020-10-27 2023-12-01 Pfizer Composiciones de escherichia coli y metodos de las mismas
CN116744965A (zh) 2020-11-04 2023-09-12 辉瑞大药厂 用于肺炎球菌疫苗的免疫原性组合物
EP4243863A2 (en) 2020-11-10 2023-09-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022147373A1 (en) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
AU2022223712A1 (en) 2021-02-19 2023-10-05 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
EP4346893A2 (en) 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MX2023013434A (es) 2021-05-28 2023-12-12 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos.
IL312890A (en) 2021-11-18 2024-07-01 Matrivax Inc Immunogenic fusion protein preparations and methods of using them
CN118510548A (zh) 2022-01-13 2024-08-16 辉瑞公司 包含缀合的荚膜糖抗原的免疫原性组合物及其用途
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
WO2024110839A2 (en) 2022-11-22 2024-05-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2049679C (en) * 1990-08-24 2005-06-21 Sushil G. Devare Hepatitis c assay utilizing recombinant antigens
DE4041304A1 (de) * 1990-12-21 1992-06-25 Mikrogen Molekularbiol Entw Von strukturproteinen des hepatitis c-virus abgeleitete polypeptide, testkits, die diese polypeptide enthalten und impfstoffe gegen infektionen von hepatitis c-viren
JP3516681B2 (ja) * 1991-06-24 2004-04-05 カイロン コーポレイション Ｃ型肝炎ウイルス（ｈｃｖ）ポリペプチド
MA22842A1 (fr) * 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
NZ253137A (en) * 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
JPH06279500A (ja) * 1992-09-30 1994-10-04 Imuno Japan:Kk ＨＢｃ融合蛋白粒子およびその製造方法
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines

Also Published As

Publication number Publication date
HUP9901901A3 (en) 2000-03-28
CA2222456A1 (en) 1997-01-16
GB9513261D0 (en) 1995-09-06
BR9609258A (pt) 1999-05-11
KR19990028505A (ko) 1999-04-15
AU6304996A (en) 1997-01-30
NO976060L (no) 1998-02-17
PL324906A1 (en) 1998-06-22
CZ422397A3 (cs) 1998-06-17
MX9710523A (es) 1998-09-30
WO1997001640A3 (en) 1997-05-15
IL122589A0 (en) 1998-06-15
WO1997001640A2 (en) 1997-01-16
TR199701713T1 (xx) 1998-05-21
HUP9901901A2 (hu) 1999-09-28
EP0835318A2 (en) 1998-04-15
NO976060D0 (no) 1997-12-23
JPH11508769A (ja) 1999-08-03

Similar Documents

Publication Publication Date Title
GB9513261D0 (en) Vaccines
PL332633A1 (en) Vaccines
EP0958373A4 (en) Vaccines.
GB9410922D0 (en) Vaccines
ZA957482B (en) Vaccine
GB9526433D0 (en) Vaccine component
GB9525657D0 (en) Vaccines
GB9514088D0 (en) Vaccines
GB9524825D0 (en) Vaccines
GB9508326D0 (en) Vaccines
ZA962036B (en) Vaccines
ZA964644B (en) Vaccines
GB9512827D0 (en) Vaccines
GB9513107D0 (en) Vaccines
GB9513260D0 (en) Vaccines
GB9517269D0 (en) Vaccines
GB9513443D0 (en) Vaccines
GB9518946D0 (en) Vaccines
GB9406708D0 (en) Vaccines
GB9419969D0 (en) Vaccine
ZA973824B (en) Vaccines
GB9526438D0 (en) Vaccine component
GB9418058D0 (en) Vaccines
ZA952370B (en) Vaccines
ZA956796B (en) Vaccines